These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 34628568)

  • 1. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study.
    Ripabelli G; Tamburro M; Buccieri N; Adesso C; Caggiano V; Cannizzaro F; Di Palma MA; Mantuano G; Montemitro VG; Natale A; Rodio L; Sammarco ML
    J Community Health; 2022 Apr; 47(2):211-225. PubMed ID: 34628568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
    Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
    BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
    Maruyama A; Sawa T; Teramukai S; Katoh N
    J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Results from an active pharmacovigilance study in central Italy.
    Ripabelli G; Sammarco ML; D'Amico A; De Dona R; Iafigliola M; Parente A; Samprati N; Santagata A; Adesso C; Natale A; Di Palma MA; Cannizzaro F; Romano R; Licianci A; Tamburro M
    Hum Vaccin Immunother; 2022 Nov; 18(6):2126668. PubMed ID: 36315849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older.
    Tamburro M; Ripabelli G; D'Amico A; De Dona R; Iafigliola M; Parente A; Samprati N; Santagata A; Adesso C; Natale A; Di Palma MA; Cannizzaro F; Sammarco ML
    J Community Health; 2022 Oct; 47(5):814-821. PubMed ID: 35750980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
    Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events following BNT162b2 mRNA COVID-19 vaccination among healthcare workers: A single-centre experience in Malaysia.
    Gan LL; Zahidah AR; Hazirah T; Nabilah HK; Aisyah Z; Amin INM; Ng DCE
    Med J Malaysia; 2022 May; 77(3):300-305. PubMed ID: 35638485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021.
    Fabiani M; Ramigni M; Gobbetto V; Mateo-Urdiales A; Pezzotti P; Piovesan C
    Euro Surveill; 2021 Apr; 26(17):. PubMed ID: 33928898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers.
    Ruiz-Villaverde R; Rivera-Izquierdo M; Gil-Villalba A; Pegalajar-García MD; Pérez-Rojas J; Soler-Iborte E; Valero-Ubierna MC
    Int J Dermatol; 2022 Oct; 61(10):1289-1293. PubMed ID: 35775137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events and Immunogenicity of mRNA-Based COVID-19 Vaccine among Healthcare Workers: A Single-Centre Experience.
    Sauserienė J; Liseckienė I; Neverauskė V; Šepetauskienė E; Serapinas D; Mačinskas Š; Šitkauskienė B; Bajoriūnienė I; Vaičiūnienė R; Valius L
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334616
    [No Abstract]   [Full Text] [Related]  

  • 13. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
    Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E
    J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host factors and history of SARS-CoV-2 infection impact the reactogenicity of BNT162b2 mRNA vaccine: results from a cross-sectional survey on 7,014 workers in healthcare.
    Ughi N; Del Gaudio F; Dicuonzo A; Orso M; Micheloni G; Puoti M; Pani A; Scaglione F; Zoppini L; Rossetti C; Epis OM; Bellavia G; Giroldi S; Moreno M; Bosio M
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7985-7996. PubMed ID: 34982462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19.
    Halder A; Imamura H; Condon S; Boroughs K; Nilsson SC; Anderson T; Caterson ID
    Intern Med J; 2022 Jan; 52(1):121-124. PubMed ID: 35060290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021.
    Ossato A; Tessari R; Trabucchi C; Zuppini T; Realdon N; Marchesini F
    Eur J Hosp Pharm; 2023 Jul; 30(4):e15. PubMed ID: 34315774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.